openPR Logo
Press release

Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA

Systemic Lupus Erythematosus Pipeline Analysis - Anthera

The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development.

Explore report sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample

Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the immune system attacks its own tissues and can cause widespread inflammation and tissue damage in the affected organs. Some of the common symptoms of systemic lupus erythematosus include oral ulcers, sun sensitivity, heart problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes, fatigue, swelling and pain in the joints. Systemic lupus erythematosus is being treated using a combination approach as number of organs are involved. Therefore, various combination therapies are being used to improve quality of life of the patients. Also, combining novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.

The research also found that various companies have collaborated for the development of systemic lupus erythematosus pipeline.

Browse report at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis

Some of the key players developing drugs for systemic lupus erythematosus include Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA and others.

Systemic Lupus Erythematosus Pipeline Analysis
• By Phase
• By Route of Administration
• By Target
• By Company

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA here

News-ID: 1270208 • Views:

More Releases from P&S Intelligence - Pharmaceuticals

Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, Eli Lilly and Company, AstraZeneca, Boehringer Ingelheim
Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, El …
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation. Download report sample at: http://bit.ly/2eqiPu5 **Various collaborations for CDK inhibitors drug development Eli Lilly
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials and Developments
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials …
The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development. As per the findings of the research, most of the drug candidates are being developed to be administered by oral route. Explore report sample at: https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis/report-sample Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to,
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent and Collaborations
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent …
Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development. Explore report sample at: https://www.psmarketresearch.com/market-analysis/japanese-encephalitis-therapeutics-pipeline/report-sample The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development.
mTOR Inhibitors Therapeutics Pipeline - Analysis, Clinical Trials, Collaborations and Developments
mTOR Inhibitors Therapeutics Pipeline - Analysis, Clinical Trials, Collaboration …
According to the research findings, most of the drug candidates that act as mTOR inhibitors are being developed as small molecules, further supported by the fact that small molecules have several advantages such as it can be manufactured with production rate higher than any other molecule types. Explore report sample at: https://www.psmarketresearch.com/market-analysis/mtor-inhibitors-therapeutics/report-sample The positive clinical results of mTOR inhibitors drug candidates is a key factor driving the pipeline growth. For instance, F.

All 5 Releases


More Releases for Systemic

Systemic Aspergillosis and Systemic Candidiasis Market Share, Sales Channels and …
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study. The systemic aspergillos is and systemic candidiasis market is expected to reach US$ 8,247.5 million by 2027 from US$ 6,056.3 million in 2019. The market is estimated to grow at a CAGR of 4.0% from 2020 to 2027. To get sample Copy of the report, along with
Systemic Aspergillosis and Systemic Candidasis Market Company Insights & SWOT An …
Well-research Systemic Aspergillosis and Systemic Candidasis market report serves as best help in the successful product launch strategy. It becomes easy for business participants to formulate best market strategies and plans beneficial for enhancing organization growth. Such an extensive market research report allows business players to better understand entire market environment. In order to establish the presence in the market, industries need to know more about present economic conditions and
Systemic Aspergillosis and Systemic Candidiasis Treatment Market Insight & Futur …
(Portland, United States): Avail a detailed research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the Systemic Aspergillosis and Systemic Candidiasis Treatment Market in the latest research report added by Big Market Research. The recent research report on the global Systemic Aspergillosis and Systemic Candidiasis Treatment Market presents the latest industry data and future trends, allowing you to recognize the products and end
Systemic Aspergillosis and Systemic Candidasis Market to Witness an Outstanding …
LOS ANGELES, UNITED STATES - The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Systemic Aspergillosis and Systemic Candidasis market. It includes Porter’s Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Systemic Aspergillosis and Systemic Candidasis Market. We have
Systemic Aspergillosis and Systemic Candidiasis Market: Size & Trends Shows a Ra …
The Global Systemic Aspergillosis and Systemic Candidiasis Market is expected to reach US$ 8,247.5 million by 2027 from US$ 6,056.3 million in 2019; it is estimated to grow at a CAGR of 4% from 2021 to 2027. Candida Auris is a fungus that poses a serious global health threat. It causes serious illness in hospitalized patients in the United States and other countries. Patients may remain colonized with C. auris for
Systemic Aspergillosis and Systemic Candidasis Market Size, Growth, Trends | Ind …
Complete study of the global Systemic Aspergillosis and Systemic Candidasis market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Systemic Aspergillosis and Systemic Candidasis industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed